14 results on '"Hierl M"'
Search Results
2. ChemInform Abstract: NUCLEOPHILIC CATALYSIS BY POLYETHYLENIMINES WITH COVALENTLY ATTACHED 4-DIALKYLAMINOPYRIDINE
- Author
-
HIERL, M. A., primary, GAMSON, E. P., additional, and KLOTZ, I. M., additional
- Published
- 1980
- Full Text
- View/download PDF
3. Selective and brain-penetrant HCN1 inhibitors reveal links between synaptic integration, cortical function, and working memory.
- Author
-
Harde E, Hierl M, Weber M, Waiz D, Wyler R, Wach JY, Haab R, Gundlfinger A, He W, Schnider P, Paina M, Rolland JF, Greiter-Wilke A, Gasser R, Reutlinger M, Dupont A, Roberts S, O'Connor EC, Bartels B, and Hall BJ
- Subjects
- Rats, Animals, Humans, Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels metabolism, Brain metabolism, Potassium Channels metabolism, Memory, Short-Term
- Abstract
Hyperpolarization-activated and cyclic-nucleotide-gated 1 (HCN1) ion channels are proposed to be critical for cognitive function through regulation of synaptic integration. However, resolving the precise role of HCN1 in neurophysiology and exploiting its therapeutic potential has been hampered by minimally selective antagonists with poor potency and limited in vivo efficiency. Using automated electrophysiology in a small-molecule library screen and chemical optimization, we identified a primary carboxamide series of potent and selective HCN1 inhibitors with a distinct mode of action. In cognition-relevant brain circuits, selective inhibition of native HCN1 produced on-target effects, including enhanced excitatory postsynaptic potential summation, while administration of a selective HCN1 inhibitor to rats recovered decrement working memory. Unlike prior non-selective HCN antagonists, selective HCN1 inhibition did not alter cardiac physiology in human atrial cardiomyocytes or in rats. Collectively, selective HCN1 inhibitors described herein unmask HCN1 as a potential target for the treatment of cognitive dysfunction in brain disorders., Competing Interests: Declaration of interests During the course of this study, E.H., M.H., M.W., R.H., D.W., R.W., J.-Y.W., A.G., P.S., A.G.-W., R.G., M.R., A.D., S.R., E.C.O., B.B., and B.J.H. are or were employees at F. Hoffmann-La Roche Ltd. and may be shareholders of F. Hoffmann-La Roche Ltd; M.P. and J.-F.R. are employees at Axxam. W.H. is an employee at WuXi AppTec (Wuhan) Co. A patent application (WO2021110574) was filed that includes some of the data described in this article., (Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
4. Emerging Gene Therapeutics for Epidermolysis Bullosa under Development.
- Author
-
Bischof J, Hierl M, and Koller U
- Subjects
- Humans, Skin metabolism, Epidermis metabolism, Blister, Mutation, Epidermolysis Bullosa genetics, Epidermolysis Bullosa therapy, Epidermolysis Bullosa pathology
- Abstract
The monogenetic disease epidermolysis bullosa (EB) is characterised by the formation of extended blisters and lesions on the patient's skin upon minimal mechanical stress. Causal for this severe condition are genetic mutations in genes, leading to the functional impairment, reduction, or absence of the encoded protein within the skin's basement membrane zone connecting the epidermis to the underlying dermis. The major burden of affected families justifies the development of long-lasting and curative therapies operating at the genomic level. The landscape of causal therapies for EB is steadily expanding due to recent breakthroughs in the gene therapy field, providing promising outcomes for patients suffering from this severe disease. Currently, two gene therapeutic approaches show promise for EB. The clinically more advanced gene replacement strategy was successfully applied in severe EB forms, leading to a ground-breaking in vivo gene therapy product named beremagene geperpavec (B-VEC) recently approved from the US Food and Drug Administration (FDA). In addition, the continuous innovations in both designer nucleases and gene editing technologies enable the efficient and potentially safe repair of mutations in EB in a potentially permanent manner, inspiring researchers in the field to define and reach new milestones in the therapy of EB.
- Published
- 2024
- Full Text
- View/download PDF
5. Tritium Labeling of Neuromedin S by Conjugation with [ 3 H] N -Succinimidyl Propionate.
- Author
-
Edelmann MR, Erny J, Guba W, and Hierl M
- Abstract
The human neuropeptide neuromedin S (NMS) consists of 33 amino acids. The introduction of tritium atoms into NMS has not been described so far. This represents a gap for using [
3 H]NMS in radioreceptor binding assays or in tracking and monitoring their metabolic pathway. Two approaches for the incorporation of tritium into NMS were explored in this study: (1) halogenation at the His-18 residue followed by catalyzed iodine-127/tritium exchange and (2) conjugation of tritiated N -succinimidyl-[2,3-3 H3 ]propionate ([3 H]NSP) to at least one of the three available primary amines of amino acids Ile-1, Lys-15, and Lys-16 in the peptide sequence. Although iodination of histidine was achieved, subsequent iodine-127/deuterium exchange was unsuccessful. Derivatization at the three possible amino positions in the peptide using nonradioactive NSP resulted in a mixture of unconjugated NSM and 1- to 3-conjugations at different amino acids in the peptide sequence. Each labeling position in the mixture was assigned following detailed LC-MS/MS analysis. After separating the mixture, it was shown in an in vitro fluorometric imaging plate reader (FLIPR) and in a competitive binding assay that the propionyl-modified NMS derivatives were comparable to the unlabeled NMS, regardless of the degree of labeling and the labeling position(s). A molecular simulation with NMS in the binding pocket of the protein neuromedin U receptor 2 (NMUR2 ) confirmed that the possible labeling positions are located outside the binding region of NMUR2 . Tritium labeling was achieved at the N-terminal Ile-1 using [3 H]NSP in 7% yield with a radiochemical purity of >95% and a molar activity of 90 Ci/mmol. This approach provides access to tritiated NMS and enables new investigations to characterize NMS or corresponding NMS ligands., Competing Interests: The authors declare the following competing financial interest(s): All authors are in paid employment by the company F. Hoffmann-La Roche AG during the completion of the study., (© 2023 The Authors. Published by American Chemical Society.)- Published
- 2023
- Full Text
- View/download PDF
6. Anaesthesia and orphan disease: Rapid sequence induction in systemic mastocytosis.
- Author
-
Unterbuchner C, Hierl M, Seyfried T, and Metterlein T
- Subjects
- Humans, Laparotomy methods, Male, Mastocytosis, Systemic diagnosis, Middle Aged, Rare Diseases diagnosis, Rocuronium, Sugammadex, Time Factors, Androstanols administration & dosage, Anesthesia methods, Mastocytosis, Systemic surgery, Neuromuscular Nondepolarizing Agents administration & dosage, Rare Diseases surgery, gamma-Cyclodextrins administration & dosage
- Published
- 2017
- Full Text
- View/download PDF
7. Complementary and Alternative Medicine: A Clinical Study in 1,016 Hematology/Oncology Patients.
- Author
-
Hierl M, Pfirstinger J, Andreesen R, Holler E, Mayer S, Wolff D, and Vogelhuber M
- Subjects
- Attitude of Health Personnel, Drug Interactions, Female, Germany epidemiology, Health Knowledge, Attitudes, Practice, Humans, Male, Middle Aged, Patient Care Team, Physician-Patient Relations, Complementary Therapies statistics & numerical data, Disclosure statistics & numerical data, Hematologic Diseases therapy, Neoplasms therapy
- Abstract
Introduction: Surveys state a widespread use of complementary and alternative medicine (CAM) in patients with malignant diseases. CAM methods might potentially interfere with the metabolization of tumor-specific therapy. However, there is little communication about CAM use in hematology/oncology patients between patients, CAM providers, and oncologists., Patients and Methods: A self-administered questionnaire was handed out to all patients attending to the hematology/oncology outpatient clinic of Regensburg University Hospital. Subsequently, a chart review of all CAM users was performed., Results: Questionnaires of 1,016 patients were analyzed. Of these patients, 30% used CAM, preferably vitamins and micronutrients. Main information sources for CAM methods were physicians/nonmedical practitioners and friends/relatives. CAM therapies were provided mainly by licensed physicians (29%), followed by nonmedical practitioners (14%) and the patients themselves (13%). Although 62% of the CAM users agreed that the oncologist may know about their CAM therapy, a chart entry about CAM use was found only in 41%., Conclusion: CAM is frequently used by hematology/oncology patients. Systematic communication about CAM is essential to avoid possible drug interactions., (© 2017 S. Karger AG, Basel.)
- Published
- 2017
- Full Text
- View/download PDF
8. High-throughput TR-FRET assays for identifying inhibitors of LSD1 and JMJD2C histone lysine demethylases.
- Author
-
Yu V, Fisch T, Long AM, Tang J, Lee JH, Hierl M, Chen H, Yakowec P, Schwandner R, and Emkey R
- Subjects
- Amino Acid Sequence, Enzyme Inhibitors metabolism, Immunoassay methods, Lysine metabolism, Methylation, Molecular Sequence Data, Peptides metabolism, Enzyme Inhibitors pharmacology, Fluorescence Resonance Energy Transfer methods, High-Throughput Screening Assays methods, Histone Demethylases antagonists & inhibitors, Jumonji Domain-Containing Histone Demethylases antagonists & inhibitors
- Abstract
Lysine demethylase 1 (LSD1) and Jumonji C domain-containing oxygenase D2C (JMJD2C) participate in regulating the methylation status of histone H3 lysine residues. In some contexts, LSD1 and JMJD2C activity causes enhanced cellular proliferation, which may lead to tumorigenesis. The authors explored the utility of time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassays, which employed peptides consisting of the first 21 amino acids of histone H3 in which lysine 4 (H3K4) or lysine 9 (H3K9) was methylated (me) to quantify LSD1 and JMJD2C activity. The LSD1 assay monitored demethylation of the H3K4me1 peptide using an antibody that recognizes H3K4me1 but not the unmethylated peptide product. The JMJD2C assay measured demethylation of H3K9me3 with an antibody that selectively recognizes H3K9me2. The optimized conditions resulted in robust assays (Z' > 0.7) that required only 3 to 6 nM of enzyme in a reaction volume of 6 to 10 µL. These assays were used to compare the activity of different LSD1 constructs and to determine the apparent K(m) of each JMJD2C substrate. Finally, both assays were used in a high-throughput setting for identifying demethylase inhibitors. Compounds discovered by these TR-FRET methods may lead to powerful tools for ascertaining the roles of demethylases in a cellular context and ultimately for potential cancer treatments.
- Published
- 2012
- Full Text
- View/download PDF
9. Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain.
- Author
-
Bregman H, Berry L, Buchanan JL, Chen A, Du B, Feric E, Hierl M, Huang L, Immke D, Janosky B, Johnson D, Li X, Ligutti J, Liu D, Malmberg A, Matson D, McDermott J, Miu P, Nguyen HN, Patel VF, Waldon D, Wilenkin B, Zheng XM, Zou A, McDonough SI, and DiMauro EF
- Subjects
- Acetamides pharmacokinetics, Acetamides pharmacology, Administration, Oral, Analgesics pharmacokinetics, Analgesics pharmacology, Animals, Binding Sites, Cell Line, ERG1 Potassium Channel, Ether-A-Go-Go Potassium Channels antagonists & inhibitors, Formaldehyde, Ganglia, Spinal cytology, Humans, In Vitro Techniques, Microsomes, Liver metabolism, NAV1.1 Voltage-Gated Sodium Channel, Neurons drug effects, Neurons physiology, Pain Measurement, Patch-Clamp Techniques, Rats, Sodium Channel Blockers pharmacokinetics, Sodium Channel Blockers pharmacology, Sodium Channels, Solubility, Structure-Activity Relationship, Tetrodotoxin pharmacology, Triazines pharmacokinetics, Triazines pharmacology, Acetamides chemical synthesis, Analgesics chemical synthesis, Nerve Tissue Proteins antagonists & inhibitors, Pain drug therapy, Sodium Channel Blockers chemical synthesis, Triazines chemical synthesis
- Abstract
Clinical human genetic studies have recently identified the tetrodotoxin (TTX) sensitive neuronal voltage gated sodium channel Nav1.7 (SCN9A) as a critical mediator of pain sensitization. Herein, we report structure-activity relationships for a novel series of 2,4-diaminotriazines that inhibit hNav1.7. Optimization efforts culminated in compound 52, which demonstrated pharmacokinetic properties appropriate for in vivo testing in rats. The binding site of compound 52 on Nav1.7 was determined to be distinct from that of local anesthetics. Compound 52 inhibited tetrodotoxin-sensitive sodium channels recorded from rat sensory neurons and exhibited modest selectivity against the hERG potassium channel and against cloned and native tetrodotoxin-resistant sodium channels. Upon oral administration to rats, compound 52 produced dose- and exposure-dependent efficacy in the formalin model of pain.
- Published
- 2011
- Full Text
- View/download PDF
10. Cellular transcription factor ZASC1 regulates murine leukemia virus transcription.
- Author
-
Bruce JW, Hierl M, Young JA, and Ahlquist P
- Subjects
- Animals, Cell Line, Cricetinae, Cricetulus, Gene Deletion, Gene Silencing, Genetic Complementation Test, Mutagenesis, Insertional, Terminal Repeat Sequences, Transcription Factors genetics, Host-Pathogen Interactions, Leukemia Virus, Murine physiology, Transcription Factors physiology, Transcription, Genetic, Virus Replication
- Abstract
To identify cellular processes involved in retroviral infection, we employed a high-volume forward genetic screen of insertionally mutagenized somatic cells using a murine leukemia virus (MLV) vector. This approach identified a clonal cell line that exhibited approximately 10-fold reduced gene expression from MLV vectors following infection despite supporting normal levels of MLV reverse transcription and integration. The defect in this cell line was specific for the MLV long terminal repeat (LTR) promoter, as normal levels of reporter gene expression were obtained from both an internal cytomegalovirus (CMV) promoter contained within an LTR-defective MLV vector and LTR expression from an avian sarcoma and leukosis virus (ASLV) vector. Complementation and shRNA knockdown experiments demonstrated that the defective gene in these cells is ZASC1 (ZNF639), a transcription factor with strong links to cancer and inherited ataxias. We demonstrated that ZASC1 is a sequence-specific DNA binding protein with three closely related binding sites located within the MLV LTR promoter, but it does not bind to the ASLV promoter. Mutating these putative ZASC1 binding sites significantly reduced levels of MLV gene expression. While wild-type ZASC1 activated expression from the MLV promoter, a green fluorescent protein-ZASC1 fusion protein showed dominant-negative inhibition of MLV gene expression. These studies identify the cellular transcription factor ZASC1 as an activator of MLV gene expression and provide tools that should be useful in studying the links between ZASC1 and human diseases.
- Published
- 2010
- Full Text
- View/download PDF
11. Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain.
- Author
-
Gao B, Hierl M, Clarkin K, Juan T, Nguyen H, van der Valk M, Deng H, Guo W, Lehto SG, Matson D, McDermott JS, Knop J, Gaida K, Cao L, Waldon D, Albrecht BK, Boezio AA, Copeland KW, Harmange JC, Springer SK, Malmberg AB, and McDonough SI
- Subjects
- Animals, Chronic Disease, Humans, Hyperalgesia diagnosis, Male, Rats, Rats, Sprague-Dawley, Treatment Outcome, Analgesics administration & dosage, Hyperalgesia drug therapy, Hyperalgesia physiopathology, Nicotinic Agonists administration & dosage, Pain Measurement drug effects
- Abstract
Nicotinic acetylcholine receptors (nAChRs) are longstanding targets for a next generation of pain therapeutics, but the nAChR subtypes that govern analgesia remain unknown. We tested a series of nicotinic agonists, including many molecules used or tried clinically, on a panel of cloned neuronal nAChRs for potency and selectivity using patch-clamp electrophysiology and a live cell-based fluorescence assay. Nonselective nicotinic agonists as well as compounds selective either for alpha4beta2 or for alpha7 nAChRs were then tested in the formalin and complete Freund's adjuvant models of pain. Nonselective nAChR agonists ABT-594 and varenicline were effective analgesics. By contrast, the selective alpha4beta2 agonist ispronicline and a novel alpha4beta2-selective potentiator did not appear to produce analgesia in either model. alpha7-selective agonists reduced the pain-related endpoint, but the effect could be ascribed to nonspecific reduction of movement rather than to analgesia. Neither selective nor nonselective alpha7 nicotinic agonists affected the release of pro-inflammatory cytokines in response to antigen challenge. Electrophysiological recordings from spinal cord slice showed a strong nicotine-induced increase in inhibitory synaptic transmission that was mediated partially by alpha4beta2 and only minimally by alpha7 subtypes. Taken with previous studies, the results suggest that agonism of alpha4beta2 nAChRs is necessary but not sufficient to produce analgesia, and that the spinal cord is a key site where the molecular action of nAChRs produces analgesia., (Copyright 2010 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
12. Synthesis and activity of substituted carbamates as potentiators of the alpha4beta2 nicotinic acetylcholine receptor.
- Author
-
Springer SK, Woodin KS, Berry V, Boezio AA, Cao L, Clarkin K, Harmange JC, Hierl M, Knop J, Malmberg AB, McDermott JS, Nguyen HQ, Waldon D, Albrecht BK, and McDonough SI
- Subjects
- Acetylcholine chemistry, Calcium chemistry, Carbamates chemistry, Drug Design, Humans, Models, Chemical, Nervous System metabolism, Neurons metabolism, Patch-Clamp Techniques, Pyrazoles chemistry, Pyridines chemistry, Receptors, Nicotinic metabolism, Structure-Activity Relationship, Chemistry, Pharmaceutical methods, Receptors, Nicotinic chemistry
- Abstract
The synthesis and structure-activity relationship of a series of carbamate potentiators of alpha4beta2 nAChR is reported herein. These compounds were highly selective for alpha4beta2 over other nAChR subtypes. In addition, compounds increased the response of alpha4beta2 nAChRs to acetylcholine, as measured with patch-clamp electrophysiology.
- Published
- 2008
- Full Text
- View/download PDF
13. Discovery and optimization of substituted piperidines as potent, selective, CNS-penetrant alpha4beta2 nicotinic acetylcholine receptor potentiators.
- Author
-
Albrecht BK, Berry V, Boezio AA, Cao L, Clarkin K, Guo W, Harmange JC, Hierl M, Huang L, Janosky B, Knop J, Malmberg A, McDermott JS, Nguyen HQ, Springer SK, Waldon D, Woodin K, and McDonough SI
- Subjects
- Animals, Combinatorial Chemistry Techniques, Disease Models, Animal, Humans, Molecular Structure, Piperidines chemistry, Rats, Receptors, Nicotinic chemistry, Structure-Activity Relationship, Central Nervous System drug effects, Nicotinic Agonists pharmacology, Piperidines chemical synthesis, Piperidines pharmacology, Receptors, Nicotinic drug effects
- Abstract
The discovery of a series of small molecule alpha4beta2 nAChR potentiators is reported. The structure-activity relationship leads to potent compounds selective against nAChRs including alpha3beta2 and alpha3beta4 and optimized for CNS penetrance. Compounds increased currents through recombinant alpha4beta2 nAChRs, yet did not compete for binding with the orthosteric ligand cytisine. High potency and efficacy on the rat channel combined with good PK properties will allow testing of the alpha4beta2 potentiator mechanism in animal models of disease.
- Published
- 2008
- Full Text
- View/download PDF
14. Cloning of novel human SEC14p-like proteins: ligand binding and functional properties.
- Author
-
Kempná P, Zingg JM, Ricciarelli R, Hierl M, Saxena S, and Azzi A
- Subjects
- Amino Acid Sequence, Carrier Proteins metabolism, Cells, Cultured, Chromatography, Thin Layer, Cloning, Molecular, DNA Primers chemistry, Electrophoretic Mobility Shift Assay, Genetic Complementation Test, Humans, Ligands, Membrane Proteins metabolism, Molecular Sequence Data, Phosphatidylcholines metabolism, Phosphatidylinositol 3-Kinases genetics, Phosphatidylinositols metabolism, Phospholipid Transfer Proteins, Polymerase Chain Reaction, Recombinant Fusion Proteins, Saccharomyces cerevisiae, Sequence Homology, Amino Acid, Signal Transduction, Substrate Specificity, Carrier Proteins genetics, Membrane Proteins genetics, Phosphatidylinositol 3-Kinases metabolism, Saccharomyces cerevisiae Proteins, Tocopherols metabolism
- Abstract
We describe the cloning and expression of two novel genes highly similar to the tocopherol-associated protein (hTAP/SEC14L2/SPF). Immunoprecipitation of the three recombinant hTAPs and extraction of their associated lipid-soluble molecules indicates that they bind not just tocopherols, but also phosphatidylinositol, phosphatidylcholine, and phosphatidylglycerol. Ligand competition analysis by isoelectric point mobility shift assay indicates that phosphatidylcholine, tocopherols, and tocopheryl-succinate compete with phosphatidylinositol binding to hTAPs. To investigate a possible function of hTAPs on enzymes involved in phospholipids metabolism, the activity of recombinant phosphatidylinositol 3-kinase (PI3Kgamma/p110gamma) was tested. Recombinant hTAPs reduce in vitro the activity of the recombinant catalytic subunit of PI3Kgamma and stimulate it in the presence of alpha-tocopherol up to 5-fold. Immunoprecipitation of hTAP1 from cells results in co-precipitation of PI3-kinase activity, indicating a physical contact between the two proteins at a cellular level. In summary, hTAPs may modulate, in a tocopherol-sensitive manner, phosphatidylinositol-3-kinase, a central enzyme in signal transduction, cell proliferation, and apoptosis. It is possible that other phosphatidylinositol- and phosphatidylcholine-dependent signaling pathways are modulated by hTAPs and tocopherols, possibly by transporting and presenting these ligands to the corresponding enzymes.
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.